“Current evidence points to an effective pneumococcal vaccine that could begin to save lives now. We cannot afford to wait until another million children die next year. We must act now.”
President of the International Pediatric Association
Multi-valent pneumococal conjugate vaccines have the potential to save millions of children worldwide
Routine pneumococal immunization programs in North America and pneumococcal conjugate vaccine efficacy studies in Africa demonstrate that multi-valent pneumococal conjugate vaccines have the potential to save millions of children worldwide.
Routine pneumococcal immunization programs with the 7-valent pneumococcal conjugate vaccine in North America have demonstrated phenomenal vaccine health impact in protecting both the vaccinated children and the unvaccinated children and adults from pneumococcal disease and in reducing health disparities and improving child survival and health among vulnerable children.
Two vaccine efficacy studies in Africa with the 9-valent pneumococcal conjugate vaccine in The Gambia and South Africa demonstrate that multi-valent pneumococcal conjugate vaccines are safe and effective even for HIV-positive children and have the potential to make a major health impact especially in rural settings where access to treatment is limited.
One vaccine efficacy study in The Philippines with the 11-valent pneumococcal conjugate vaccine is complete and the results are expected soon. This is the only large-scale population-based study in Asia.
In order to assess and demonstrate the effectiveness of pneumococcal conjugate vaccines in Asia, PneumoADIP, WHO and other partners have identified seven countries as sites for potential large-scale vaccine evaluations.